Papaverine

Phase 3Small molecule

WWestern Galilee Hospital-Nahariya

Papaverine is one of 112 small molecule programs targeting Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaActive, not recruiting

Erectile DysfunctionActive, not recruiting

GastroenteritisActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Locally Advanced Lung Non-Small Cell CarcinomaRecruiting

HyperplasiaPhase 1

Active, not recruiting

Erectile DysfunctionPhase 2

Active, not recruiting

GastroenteritisPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Locally Advanced Lung Non-Small Cell CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Papaverine

WWestern Galilee Hospital-Nahariya

Phase 3

10 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Vidaza

1 10

REGN2810

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Locally Advanced Lung Non-Small Cell Carcinoma

NCT05136846

Q3 2028

Phase 1Recruiting

Locally-Advanced Rectal Cancer

NCT06834126

Clinical

Trials by Indication[1]

Labor Induction2 trials

IV PAPAVERINE Prior to Propess for Labor Induction

Completed·WWestern Galilee Hospital-Nahariya·Phase 4·NCT06550232·110 enrolled

Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction

Not yet recruiting·WWestern Galilee Hospital-Nahariya·N/A·NCT06547437·126 enrolled

Pediatric Patients1 trial

Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03894904·100 enrolled

ART1 trial

The Effect of Periradial Injection of Papaverine Versus Nitroglycerine on Radial Artery Diameter

Completed·KKasr El Aini Hospital·Phase 1·NCT04030663·90 enrolled

Locally-advanced Rectal Cancer1 trial

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

Recruiting·—·Phase 1·NCT06834126·36 enrolled

Erectile Dysfunction1 trial

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00080808·111 enrolled

4 more indications

Hyperplasia1 trial

Prostatic Hyperplasia Treatment and Cancer Prevention

Unknown status·MManchanda Medical Clinic·Phase 1·NCT03064282·40 enrolled

Gastroenteritis1 trial

Optimal Analgesia in Acute Gastroenteritis

Terminated·HHadassah Medical Organization·Phase 3·NCT02711241·15 enrolled

Volume1 trial

Effect of Papaverine on Renal Artery Blood Flow Volume

Completed·—·Phase 4·NCT04162834·96 enrolled

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05136846·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Papaverine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Papaverine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Papaverine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Western Galilee Hospital-Nahariya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWestern Galilee Hospital-Nahariya

Papaverine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Labor Induction2 trials

Pediatric Patients1 trial

ART1 trial

Locally-advanced Rectal Cancer1 trial

Erectile Dysfunction1 trial

Hyperplasia1 trial

Gastroenteritis1 trial

Volume1 trial

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News